Infectious diseases in the 21st century: increasing threats, fewer new treatments and a premium on prevention
Do we really need new anti-infective drugs?
Antimicrobial strategies for the prevention and treatment of cardiovascular infections
The abandonment of antibacterials: why and wherefore?
The evolution of a resistant pathogen – the case of MRSA
Good bugs and bad bugs: indications and therapies for Helicobacter pylori eradication
Passive immunization as prophylaxis: when and where will this work?
Molecular diagnostics in medical microbiology: yesterday, today and tomorrow
Targeting metalloenzymes: a strategy that works
Transcriptional profiling and drug discovery
Targeting virulence for antimicrobial chemotherapy
Pharmacology provides the context for value creation for new technologies
Emerging trends in high-throughput screening
Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors
New technologies in therapeutic antibody development
Allosteric modulators of G-protein-coupled receptors
Biosensor profiling of molecular interactions in pharmacology
Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry
Target validation